Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children aged two years and older.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe and often-fatal complication of stem-cell transplantation, driven by activation of the lectin pathway of complement. Mortality in high-risk cases can exceed 90%, with survivors frequently facing long-term renal complications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.